A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia

PaperCitations, authors & open-access status

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 207 citations, 2021 year and gold oa status.